Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
ABBOTT LABORATORIES
   2. Issuer Name and Ticker or Trading Symbol
Mylan N.V. [MYL] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
100 ABBOTT PARK ROAD		 3. Date of Earliest Transaction (Month/Day/Year)
03/31/2015
(Street)

ABBOTT PARK, IL 60064-6092		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares, nominal value euro 0.01 per share 03/31/2015   J   35,000,000 D $ 56.8912 75,000,000 I By Subsidiaries

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Call Option (Obligation to Sell) $ 56.8912 03/31/2015   J     1 03/31/2015 04/30/2015 Ordinary Shares 5,250,000 $ 0 1 I By Subsidiaries

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
ABBOTT LABORATORIES
100 ABBOTT PARK ROAD
ABBOTT PARK, IL 60064-6092		     X    
Laboratoires Fournier S.A.S.
100 ABBOTT PARK ROAD
ABBOTT PARK, IL 60064-6092		     X    
Abbott Established Products Holdings Gibraltar Ltd
100 ABBOTT PARK ROAD
ABBOTT PARK, IL 60064-6092		     X    
Abbott Investments Luxembourg S.A R.L.
100 ABBOTT PARK ROAD
ABBOTT PARK, IL 60064-6092		     X    

Signatures

 ABBOTT LABORATORIES Thomas C. Freyman   03/31/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 
Remarks:
The Ordinary Shares of Mylan N.V. ("Mylan") described in this report are held directly by Laboratoires Fournier S.A.S., Abbott Established Products Holdings (Gibraltar) Limited and Abbott Investments Luxembourg S.a r.l (collectively, the "Subsidiaries"). Each of the Subsidiaries is an indirect, wholly-owned subsidiary of Abbott Laboratories ("Abbott"). In Abbott's capacity as the ultimate corporate parent of the Subsidiaries, Abbott may be deemed to indirectly beneficially own such Ordinary Shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Securities and Exchange Commission thereunder. On March 31, 2015, the Subsidiaries entered into an Underwriting Agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC and Goldman Sachs & Co., as representatives of the several underwriters named therein, and Mylan relating to an underwritten public resale offering by the Subsidiaries of an aggregate of  35,000,000 Ordinary Shares.  The purchase price to be received by the Subsidiaries pursuant to the Underwriting Agreement is $56.89125 per Ordinary Share.  Pursuant to the Underwriting Agreement, Abbott Investments Luxembourg S.a r.l, for no additional consideration, granted the underwriters a 30-day option to purchase up to an additional 5,250,000 Ordinary Shares at the same price per Ordinary Share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.